Study Of The Safety And Pharmacokinetics Of CE-326,597 In Patients With Asymptomatic Gallstones
Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
The study is designed to assess whether repeated dosing with CE-326,597 will cause patients
with asymptomatic gallstones (as detected on screening abdominal ultrasound) to become
symptomatic. In addition, the study will characterize the pharmacokinetics of CE-326,597.